UNICOR-v has the potential to protect against future epidemics caused by a coronavirus jumping from animals to humans, but also against new variants emerging from SARS-Cov-2
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
The company will now be allowed to sell its proprietary and validated tinctures, gummies, and capsules across the UK
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
The aim is to strengthen industry-academia cooperation
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The proposed scheme to include low-income NRIs under Ayushman Bharat (PM-JAY) would ensure life-long coverage for each individual along with their spouses
Subscribe To Our Newsletter & Stay Updated
